TORONTO, ON–(Marketwired – November 17, 2016) – Delivra Corp. (“Delivra”, or “the Company”) (TSX VENTURE: DVA) announced today some changes to the executive team. Chris Schnarr, President and Chief Financial Officer of Delivra is resigning effective November 18, 2016. Mr. Schnarr will remain available to the company for transitional and other business matters going forward. Pascal Attard has been promoted to the position of Vice President, Finance.
Mr. Attard is a Chartered Professional Accountant and has served as Controller of Delivra since 2015. Prior to joining Delivra, Pascal was Controller, Red Tiger Mining Inc. and Manager, McGovern, Hurley, Cunningham, LLP a mid-market accounting firm where he received his CPA designation.
Delivra will look to deepen the technical expertise of its management team in 2017 enabling the company to more aggressively pursue its US expansion strategy. Therefore the board has commenced a search for an individual with significant experience in consumer healthcare and pharmaceuticals and international licensing.
“On behalf of the board, I would like to thank Chris for his significant contributions to the Company and for building a strong team that will allow us to continue to expand our offering. Our board and management team remains focused on our strategy of monetizing our proprietary LivRelief products while advancing our transdermal platform delivery system as a safe, more effective alternative for a broad range of conditions. Our next phase is to accelerate licensing agreements beyond OTC and to leverage our delivery system in pharmaceutical applications” stated Dr. Joseph Gabriele, Chairman and Chief Executive Officer of Delivra.
ABOUT DELIVRA CORP.
Delivra Corp. is a developer of transdermal technologies for the delivery of pharmaceutical and natural molecules through the skin, rather than via pills. Delivra manufactures and sells a growing line of natural topical creams under the LivRelief™ brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and sports performance. LivRelief™ products are available in pharmacies, grocery chains, and independent health food stores across Canada, and on-line at livrelief.com. LivRelief™ products are also available on-line and on Amazon in the United States. In parallel with its consumer products business, Delivra also has a mandate to license its unique, proven, and patent-pending delivery platform to global pharmaceutical companies for the transdermal delivery of third party active ingredients to treat a broad range of conditions. With a global transdermal drug delivery market forecast to grow to USD $40 billion by 2018 (Source: Kelly Scientific), Delivra believes the licensing opportunity is robust. Delivra is headquartered in Burlington, Ontario and has a research and development laboratory in Charlottetown, PEI.
Further information on Delivra can be found at www.delivracorp.com, www.livrelief.com for Canada and www.livrelief.com/us for the United States.
The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in the Company’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.
For more information, please contact:
Investor Relations:
Nicole Marchand
416-428-3533
[email protected]
